Crossmark

Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-018-4910-z

Published Online: 2018-08-09

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Borrie, Adrienne E.

Rose, Rhiannon V.

Choi, Yun-Hee

Perera, Francisco E.

Read, Nancy

Sexton, Tracy

Lock, Michael

Vandenberg, Theodore A.

Hahn, Karin

Dinniwell, Robert

Younus, Jawaid

Logan, Diane

Potvin, Kylea

Yaremko, Brian

Yu, Edward

Lenehan, John

Welch, Stephen

Tyndale, Rachel F.

Teft, Wendy A.

Kim, Richard B. https://orcid.org/0000-0001-8148-1632
Funding

Funding for this research was provided by:

Cancer Care Ontario (Research Chair Award)

Canadian Institutes of Health Research (201410DRS-337981-252059)

Canadian Institutes of Health Research (FDN-154294)
License Information

Text and Data Mining valid from 2018-08-09
More Information

Article History

Received: 28 July 2018

Accepted: 2 August 2018

First Online: 9 August 2018

Compliance with ethical standards

:

: RF Tyndale has consulted for Apotex and Quinn Emmanual on unrelated topics, and sits on a number of scientific advisory boards. J Younus has consulted for Amgen and AstraZeneca and has had research funding from AstraZeneca and Novartis. All other authors declare that they have no conflicts of interest to report.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.